BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 2014;311:2288-96. [PMID: 24915260 DOI: 10.1001/jama.2014.4312] [Cited by in Crossref: 119] [Cited by in F6Publishing: 106] [Article Influence: 14.9] [Reference Citation Analysis]
Number Citing Articles
1 Alkharaiji M, Anyanwagu U, Donnelly R, Idris I. Effect of Bariatric Surgery on Diagnosed Chronic Kidney Disease and Cardiovascular Events in Patients with Insulin-treated Type 2 Diabetes: a Retrospective Cohort Study from a Large UK Primary Care Database. Obes Surg 2020;30:1685-95. [PMID: 32130651 DOI: 10.1007/s11695-019-04201-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Majanovic SK, Janez A, Lefterov I, Tasic S, Cikac T. The Real-Life Effectiveness and Care Patterns of Diabetes Management Study for Balkan Region (Slovenia, Croatia, Serbia, Bulgaria): A Multicenter, Observational, Cross-Sectional Study. Diabetes Ther 2017;8:929-40. [PMID: 28695415 DOI: 10.1007/s13300-017-0288-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
3 Rados DV, Falcetta MRR, Pinto LC, Leitão CB, Gross JL. All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus: A systematic review with meta-analysis and trial sequential analysis. Diabetes Res Clin Pract 2021;173:108688. [PMID: 33549676 DOI: 10.1016/j.diabres.2021.108688] [Reference Citation Analysis]
4 Haltmeier T, Benjamin E, Beale E, Inaba K, Demetriades D. Insulin-Treated Patients with Diabetes Mellitus Undergoing Emergency Abdominal Surgery Have Worse Outcomes than Patients Treated with Oral Agents. World J Surg 2016;40:1575-82. [PMID: 26913730 DOI: 10.1007/s00268-016-3469-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Li CI, Lin CC, Cheng HM, Liu CS, Lin CH, Lin WY, Wang MC, Yang SY, Li TC. Derivation and validation of a clinical prediction model for assessing the risk of lower extremity amputation in patients with type 2 diabetes. Diabetes Res Clin Pract 2020;165:108231. [PMID: 32446799 DOI: 10.1016/j.diabres.2020.108231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Min JY, Griffin MR, Hung AM, Grijalva CG, Greevy RA, Liu X, Elasy T, Roumie CL. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes. J Gen Intern Med 2016;31:638-46. [PMID: 26921160 DOI: 10.1007/s11606-016-3633-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Yu MK, Kim SH. Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD. Clin J Am Soc Nephrol 2016;11:2104-6. [PMID: 27827307 DOI: 10.2215/CJN.10361016] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract. 2015;110:75-81. [PMID: 26361859 DOI: 10.1016/j.diabres.2015.07.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
9 Alvarez CA, Halm EA, Pugh MJV, McGuire DK, Hennessy S, Miller RT, Lingvay I, Vouri SM, Zullo AR, Yang H, Chansard M, Mortensen EM. Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study. Endocrinol Diabetes Metab 2021;4:e00170. [PMID: 33532612 DOI: 10.1002/edm2.170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bennett WL, Aschmann HE, Puhan MA, Robbins CW, Bayliss EA, Wilson R, Mularski RA, Chan WV, Leff B, Sheehan O, Glover C, Maslow K, Armacost K, Mintz S, Boyd CM. A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions. J Clin Epidemiol 2019;113:92-100. [PMID: 31059802 DOI: 10.1016/j.jclinepi.2019.03.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Lundby-Christensen L, Tarnow L, Boesgaard TW, Lund SS, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, Røder M, Mathiesen ER, Jensen T, Vestergaard H, Hedetoft C, Breum L, Duun E, Sneppen SB, Pedersen O, Hemmingsen B, Carstensen B, Madsbad S, Gluud C, Wetterslev J, Vaag A, Almdal TP. Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open 2016;6:e008376. [PMID: 26916684 DOI: 10.1136/bmjopen-2015-008376] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
12 Gale SE, Poon JL, Watson K. Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence. Pharmacotherapy 2018;38:739-57. [DOI: 10.1002/phar.2128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Saulnier PJ, Gand E, Ragot S, Bankir L, Piguel X, Fumeron F, Rigalleau V, Halimi JM, Marechaud R, Roussel R, Hadjadj S; SURDIAGENE Study group. Urinary Sodium Concentration Is an Independent Predictor of All-Cause and Cardiovascular Mortality in a Type 2 Diabetes Cohort Population. J Diabetes Res 2017;2017:5327352. [PMID: 28255559 DOI: 10.1155/2017/5327352] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
14 Messinger-rapport BJ, Gammack JK, Little MO, Morley JE. Clinical Update on Nursing Home Medicine: 2014. Journal of the American Medical Directors Association 2014;15:786-801. [DOI: 10.1016/j.jamda.2014.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
15 Anyanwagu U, Donnelly R, Idris I. Individual and Combined Relationship between Reduced eGFR and/or Increased Urinary Albumin Excretion Rate with Mortality Risk among Insulin-Treated Patients with Type 2 Diabetes in Routine Practice. Kidney Dis (Basel) 2019;5:91-9. [PMID: 31019922 DOI: 10.1159/000493731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
16 Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014;20:573-91. [PMID: 25242225 DOI: 10.1016/j.cmet.2014.08.005] [Cited by in Crossref: 269] [Cited by in F6Publishing: 249] [Article Influence: 33.6] [Reference Citation Analysis]
17 Lysy Z, Fung K, Giannakeas V, Fischer HD, Bell CM, Lipscombe LL. The Association Between Insulin Initiation and Adverse Outcomes After Hospital Discharge in Older Adults: a Population-Based Cohort Study. J Gen Intern Med 2019;34:575-82. [PMID: 30756304 DOI: 10.1007/s11606-019-04849-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Griffin MR. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study. BMC Endocr Disord 2016;16:32. [PMID: 27255309 DOI: 10.1186/s12902-016-0101-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
19 Ahuja V, A. Alvarez C, Birge JR, Syverson C. Enhancing Regulatory Decision Making for Postmarket Drug Safety. Management Science. [DOI: 10.1287/mnsc.2020.3889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Lechleitner M, Clodi M, Abrahamian H, Brath H, Brix J, Drexel H, Fasching P, Föger B, Francesconi C, Fröhlich-Reiterer E, Harreiter J, Hofer SE, Hoppichler F, Huber J, Kaser S, Kautzky-Willer A, Ludvik B, Luger A, Mader JK, Paulweber B, Pieber T, Prager R, Rami-Merhar B, Resl M, Riedl M, Roden M, Saely CH, Schelkshorn C, Schernthaner G, Sourij H, Stechemesser L, Stingl H, Toplak H, Wascher TC, Weitgasser R, Winhofer-Stöckl Y, Zlamal-Fortunat S. [Insulin therapy of type 2 diabetes mellitus (Update 2019)]. Wien Klin Wochenschr 2019;131:39-46. [PMID: 30980147 DOI: 10.1007/s00508-019-1492-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Kuo S, Yang CT, Wu JS, Ou HT. Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study. Diabetes Obes Metab 2019;21:312-20. [PMID: 30187666 DOI: 10.1111/dom.13525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitão C, Gross JL. The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials. PLoS Med 2016;13:e1001992. [PMID: 27071029 DOI: 10.1371/journal.pmed.1001992] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
23 Connor T, Martin SD, Howlett KF, Mcgee SL. Metabolic remodelling in obesity and type 2 diabetes: pathological or protective mechanisms in response to nutrient excess? Clin Exp Pharmacol Physiol 2015;42:109-15. [DOI: 10.1111/1440-1681.12315] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
24 Anyanwagu U, Mamza J, Donnelly R, Idris I. Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials. Diabetes Research and Clinical Practice 2016;121:69-85. [DOI: 10.1016/j.diabres.2016.09.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
25 Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab 2018;20:344-51. [PMID: 28771923 DOI: 10.1111/dom.13077] [Cited by in Crossref: 109] [Cited by in F6Publishing: 103] [Article Influence: 21.8] [Reference Citation Analysis]
26 Gentile G, Mastroluca D, Ruggenenti P, Remuzzi G. Novel effective drugs for diabetic kidney disease? or not? Expert Opin Emerg Drugs 2014;19:571-601. [PMID: 25376947 DOI: 10.1517/14728214.2014.979151] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
27 Chen YY, Lin YJ, Chong E, Chen PC, Chao TF, Chen SA, Chien KL. The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: a representative cohort study in Taiwan. PLoS One 2015;10:e0123116. [PMID: 25874454 DOI: 10.1371/journal.pone.0123116] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
28 Strandberg AY, Hoti FJ, Strandberg TE, Christopher S, Haukka J, Korhonen P. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine. PLoS One 2016;11:e0151910. [PMID: 27031113 DOI: 10.1371/journal.pone.0151910] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
29 Singh S. Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy. Curr Diab Rep 2014;14:563. [PMID: 25363547 DOI: 10.1007/s11892-014-0563-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
30 Murff HJ, Roumie CL, Greevy RA, Hackstadt AJ, McGowan LED, Hung AM, Grijalva CG, Griffin MR. Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer. Cancer Causes Control 2018;29:823-32. [PMID: 30022336 DOI: 10.1007/s10552-018-1058-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
31 Burne RM, Abrahamowicz M. Adjustment for time-dependent unmeasured confounders in marginal structural Cox models using validation sample data. Stat Methods Med Res 2019;28:357-71. [DOI: 10.1177/0962280217726800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
32 Dhatariya K. Pharmacotherapy for type 2 diabetes in very elderly patients: practicing nihilism or pragmatism? Age Ageing 2015;44:540-2. [PMID: 26002916 DOI: 10.1093/ageing/afv067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
33 Karwi QG, Ho KL, Pherwani S, Ketema EB, Sun QY, Lopaschuk GD. Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. Cardiovasc Res 2021:cvab120. [PMID: 33783483 DOI: 10.1093/cvr/cvab120] [Reference Citation Analysis]
34 Dhatariya K. Diabetes: the place of new therapies. Ther Adv Endocrinol Metab 2019;10:2042018818807599. [PMID: 30800266 DOI: 10.1177/2042018818807599] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Norhammar A, Bodegård J, Nyström T, Thuresson M, Nathanson D, Eriksson JW. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. Diabetes Obes Metab 2019;21:1136-45. [PMID: 30609272 DOI: 10.1111/dom.13627] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 13.3] [Reference Citation Analysis]
36 Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab 2017;19:831-41. [PMID: 28116795 DOI: 10.1111/dom.12889] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 11.2] [Reference Citation Analysis]
37 Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, Shrestha D, Qureshi MF, Md Fariduddin, Pathan MF, Jawad F, Bhattarai J, Tandon N, Somasundaram N, Katulanda P, Sahay R, Dhungel S, Bajaj S, Chowdhury S, Ghosh S, Madhu SV, Ahmed T, Bulughapitiya U, Qureshi MF, Md Fariduddin, Pathan MF, Jawad F. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab. 2015;19:577-596. [PMID: 26425465 DOI: 10.4103/2230-8210.163171] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 7.7] [Reference Citation Analysis]
38 Hanssen NMJ, Kraakman MJ, Flynn MC, Nagareddy PR, Schalkwijk CG, Murphy AJ. Postprandial Glucose Spikes, an Important Contributor to Cardiovascular Disease in Diabetes? Front Cardiovasc Med 2020;7:570553. [PMID: 33195459 DOI: 10.3389/fcvm.2020.570553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Shamshirgaran SM, Ataei J, Malek A, Iranparvar-Alamdari M, Aminisani N. Quality of sleep and its determinants among people with type 2 diabetes mellitus in Northwest of Iran. World J Diabetes 2017; 8(7): 358-364 [PMID: 28751959 DOI: 10.4239/wjd.v8.i7.358] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
40 Dailey G, Wang E. A review of cardiovascular outcomes in the treatment of people with type 2 diabetes. Diabetes Ther 2014;5:385-402. [PMID: 25515096 DOI: 10.1007/s13300-014-0091-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
41 Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW. Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. Endocrinol Diabetes Metab 2018;1:e00036. [PMID: 30815564 DOI: 10.1002/edm2.36] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
42 McDonald MI, Lawson KD. Doing it hard in the bush: Aligning what gets measured with what matters. Aust J Rural Health 2017;25:246-51. [PMID: 28205339 DOI: 10.1111/ajr.12336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
43 Mannucci E, Ferrannini E. Cardiovascular safety of insulin: Between real‐world data and reality. Diabetes Obes Metab 2017;19:1201-4. [DOI: 10.1111/dom.12967] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
44 Huang H, Yeh J. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. Diabetes Research and Clinical Practice 2019;152:103-10. [DOI: 10.1016/j.diabres.2019.04.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Yang X, Lee HM, Chan JC. Drug-subphenotype interactions for cancer in type 2 diabetes mellitus. Nat Rev Endocrinol. 2015;11:372-379. [PMID: 25801918 DOI: 10.1038/nrendo.2015.37] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
46 Bagepally BS, Chaikledkaew U, Youngkong S, Anothaisintawee T, Thavorncharoensap M, Dejthevaporn C, Thakkinstian A. Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer's Perspective. Clinicoecon Outcomes Res 2021;13:897-907. [PMID: 34712053 DOI: 10.2147/CEOR.S328433] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Pop LM, Lingvay I. The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing? Curr Diab Rep 2017;17:124. [PMID: 29063276 DOI: 10.1007/s11892-017-0954-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
48 Price HI, Agnew MD, Gamble JM. Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review. BMJ Open. 2015;5:e006341. [PMID: 25762229 DOI: 10.1136/bmjopen-2014-006341] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
49 Anabtawi A, Miles JM. Metformin: nonglycemic effects and potential novel indications. Endocr Pract. 2016;22:999-1007. [PMID: 27579542 DOI: 10.4158/ep151145.ra] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 6.6] [Reference Citation Analysis]
50 Lechleitner M, Roden M, Weitgasser R, Ludvik B, Fasching P, Hoppichler F, Kautzky-Willer A, Schernthaner G, Prager R, Wascher TC. [Insulin therapy of diabetes]. Wien Klin Wochenschr 2016;128 Suppl 2:S54-61. [PMID: 27052221 DOI: 10.1007/s00508-015-0925-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
51 Mannucci E, Giannini S, Dicembrini I. Cardiovascular effects of basal insulins. Drug Healthc Patient Saf 2015;7:113-20. [PMID: 26203281 DOI: 10.2147/DHPS.S43300] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
52 Akoumianakis I, Badi I, Douglas G, Chuaiphichai S, Herdman L, Akawi N, Margaritis M, Antonopoulos AS, Oikonomou EK, Psarros C, Galiatsatos N, Tousoulis D, Kardos A, Sayeed R, Krasopoulos G, Petrou M, Schwahn U, Wohlfart P, Tennagels N, Channon KM, Antoniades C. Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition. Sci Transl Med 2020;12:eaav8824. [PMID: 32350133 DOI: 10.1126/scitranslmed.aav8824] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
53 Alkharaiji M, Anyanwagu U, Donnelly R, Idris I. Effect of Bariatric Surgery on Cardiovascular Events and Metabolic Outcomes in Obese Patients with Insulin-Treated Type 2 Diabetes: a Retrospective Cohort Study. Obes Surg 2019;29:3154-64. [PMID: 31392579 DOI: 10.1007/s11695-019-03809-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
54 Ekström N, Svensson AM, Miftaraj M, Franzén S, Zethelius B, Eliasson B, Gudbjörnsdottir S. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. Diabetes Obes Metab 2016;18:990-8. [PMID: 27282621 DOI: 10.1111/dom.12704] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
55 Gamble J, Chibrikov E, Twells LK, Midodzi WK, Young SW, Macdonald D, Majumdar SR. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. The Lancet Diabetes & Endocrinology 2017;5:43-52. [DOI: 10.1016/s2213-8587(16)30316-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
56 Yandrapalli S, Jolly G, Horblitt A, Pemmasani G, Sanaani A, Aronow WS, Frishman WH. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1. Cardiol Rev 2020;28:177-89. [PMID: 32282393 DOI: 10.1097/CRD.0000000000000308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Wyler SF, Chun FF, Recker F, Kwiatkowski M. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau). World J Urol 2015;33:1189-96. [PMID: 25358675 DOI: 10.1007/s00345-014-1426-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
58 Jung I, Kwon H, Park SE, Han KD, Park YG, Rhee EJ, Lee WY. The Effects of Glucose Lowering Agents on the Secondary Prevention of Coronary Artery Disease in Patients with Type 2 Diabetes. Endocrinol Metab (Seoul) 2021;36:977-87. [PMID: 34645126 DOI: 10.3803/EnM.2021.1046] [Reference Citation Analysis]
59 Hung AM, Roumie CL, Greevy RA, Grijalva CG, Liu X, Murff HJ, Ikizler TA, Griffin MR. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline. Clin J Am Soc Nephrol 2016;11:2177-85. [PMID: 27827311 DOI: 10.2215/CJN.02630316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
60 Xue L, Strotmeyer ES, Zgibor J, Costacou T, Boudreau R, Kelley D, Donohue JM. Cardiovascular disease risk and the time to insulin initiation for Medicaid enrollees with type 2 diabetes. J Clin Transl Endocrinol 2020;22:100241. [PMID: 33294383 DOI: 10.1016/j.jcte.2020.100241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Spectre G, Stålesen R, Östenson CG, Hjemdahl P. Meal-induced platelet activation in diabetes mellitus type 1 or type 2 is related to postprandial insulin rather than glucose levels. Thromb Res 2016;141:93-7. [PMID: 26994470 DOI: 10.1016/j.thromres.2016.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Jil M, Rajnikant M, Richard D, Iskandar I. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study. Diabetes and Vascular Disease Research 2017;14:295-303. [DOI: 10.1177/1479164116687102] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
63 Engelmann J, Manuwald U, Rubach C, Kugler J, Birkenfeld AL, Hanefeld M, Rothe U. Determinants of mortality in patients with type 2 diabetes: a review. Rev Endocr Metab Disord 2016;17:129-37. [PMID: 27068710 DOI: 10.1007/s11154-016-9349-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
64 Roumie CL, Min JY, Greevy RA, Grijalva CG, Hung AM, Liu X, Elasy T, Griffin MR. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea. CMAJ 2016;188:E104-12. [PMID: 26811361 DOI: 10.1503/cmaj.150904] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
65 Scosyrev E. Asymptotically robust variance estimation for person-time incidence rates: Asymptotically robust variance estimation. Biom J 2016;58:474-88. [DOI: 10.1002/bimj.201400173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Pouwels KB, Voorham J, Hak E, Denig P. Identification of major cardiovascular events in patients with diabetes using primary care data. BMC Health Serv Res 2016;16:110. [PMID: 27038959 DOI: 10.1186/s12913-016-1361-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
67 Presley CA, Chipman J, Min JY, Grijalva CG, Greevy RA, Griffin MR, Roumie CL. Evaluation of Frailty as an Unmeasured Confounder in Observational Studies of Antidiabetic Medications. J Gerontol A Biol Sci Med Sci 2019;74:1282-8. [PMID: 30256914 DOI: 10.1093/gerona/gly224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol 2015;14:100. [PMID: 26249018 DOI: 10.1186/s12933-015-0260-x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 16.3] [Reference Citation Analysis]
69 Anderson TS, Lee S, Jing B, Fung K, Ngo S, Silvestrini M, Steinman MA. Prevalence of Diabetes Medication Intensifications in Older Adults Discharged From US Veterans Health Administration Hospitals. JAMA Netw Open 2020;3:e201511. [PMID: 32207832 DOI: 10.1001/jamanetworkopen.2020.1511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
70 Currie CJ, Holden SE. Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin: Editorial. Diabetes Obes Metab 2014;16:881-4. [DOI: 10.1111/dom.12349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
71 Golledge J, Quigley F, Velu R, Walker PJ, Moxon JV. Association of impaired fasting glucose, diabetes and their management with the presentation and outcome of peripheral artery disease: a cohort study. Cardiovasc Diabetol. 2014;13:147. [PMID: 25361884 DOI: 10.1186/s12933-014-0147-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
72 Buysman EK, Anderson A, Bacchus S, Ingham M. Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin. Adv Ther 2017;34:937-53. [PMID: 28251556 DOI: 10.1007/s12325-017-0500-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
73 Douros A, Dell'aniello S, Yu OHY, Suissa S. Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population‐based cohort study. Diabetes Obes Metab 2020;22:254-62. [DOI: 10.1111/dom.13893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
74 Min JY, Hackstadt AJ, Griffin MR, Greevy RA Jr, Chipman J, Grijalva CG, Hung AM, Roumie CL. Evaluation of weight change and hypoglycaemia as mediators in the association between insulin use and death. Diabetes Obes Metab 2019;21:2626-34. [PMID: 31373104 DOI: 10.1111/dom.13846] [Reference Citation Analysis]
75 Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ. Do sulphonylureas still have a place in clinical practice? The Lancet Diabetes & Endocrinology 2018;6:821-32. [DOI: 10.1016/s2213-8587(18)30025-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 27] [Article Influence: 15.8] [Reference Citation Analysis]
76 Kung FP, Tsai CF, Lu CL, Huang LC, Lu CH. Diabetes pay-for-performance program can reduce all-cause mortality in patients with newly diagnosed type 2 diabetes mellitus. Medicine (Baltimore) 2020;99:e19139. [PMID: 32049836 DOI: 10.1097/MD.0000000000019139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Mondesir FL, Brown TM, Muntner P, Durant RW, Carson AP, Safford MM, Levitan EB. Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS). Am Heart J 2016;181:43-51. [PMID: 27823692 DOI: 10.1016/j.ahj.2016.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
78 Ahuja V, Alvarez CA, Staats BR. Maintaining Continuity in Service: An Empirical Examination of Primary Care Physicians. M&SOM 2020;22:1088-106. [DOI: 10.1287/msom.2019.0808] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
79 Anyanwagu U, Mamza J, Mehta R, Donnelly R, Idris I. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. Heart 2016;102:1581-7. [DOI: 10.1136/heartjnl-2015-309164] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
80 O'Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N, Moran MR, Liss DT, Prospect TA, Ackermann RT. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. JAMA Netw Open 2018;1:e186125. [PMID: 30646315 DOI: 10.1001/jamanetworkopen.2018.6125] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
81 Liu CS, Li CI, Wang MC, Yang SY, Li TC, Lin CC. Building clinical risk score systems for predicting the all-cause and expanded cardiovascular-specific mortality of patients with type 2 diabetes. Diabetes Obes Metab 2021;23:467-79. [PMID: 33118688 DOI: 10.1111/dom.14240] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Bachmann KN, Roumie CL, Wiese AD, Grijalva CG, Buse JB, Bradford R, Zalimeni EO, Knoepp P, Dard S, Morris HL, Donahoo WT, Fanous N, Fonseca V, Katalenich B, Choi S, Louzao D, O'Brien E, Cook MM, Rothman RL, Chakkalakal RJ. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. Pharmacol Res Perspect 2020;8:e00637. [PMID: 32881317 DOI: 10.1002/prp2.637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
83 Singh AK, Singh R. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials. Diabetes Res Clin Pract 2021;172:108648. [PMID: 33421444 DOI: 10.1016/j.diabres.2021.108648] [Reference Citation Analysis]
84 Holden SE, Jenkins-Jones S, Currie CJ. Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study. PLoS One 2016;11:e0153594. [PMID: 27152598 DOI: 10.1371/journal.pone.0153594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
85 Wang F, He Y, Zhang R, Zeng Q, Zhao X. Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. Medicine (Baltimore) 2017;96:e7638. [PMID: 28885325 DOI: 10.1097/MD.0000000000007638] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
86 Stroupe KT, Bailey L, Gellad WF, Suda K, Huo Z, Martinez R, Burk M, Cunningham F, Smith BM. Veterans’ Pharmacy and Health Care Utilization Following Implementation of the Medicare Part D Pharmacy Benefit. Med Care Res Rev 2017;74:328-44. [DOI: 10.1177/1077558716643887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
87 Kalkan A, Bodegard J, Sundström J, Svennblad B, Östgren CJ, Nilsson PN, Johansson G, Ekman M. Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice. Primary Care Diabetes 2017;11:184-92. [DOI: 10.1016/j.pcd.2016.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
88 Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Res Clin Pract 2017;123:199-208. [PMID: 28056431 DOI: 10.1016/j.diabres.2016.12.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
89 Anagnostis P, Siolos P, Christou K, Gkekas NK, Kosmidou N, Athyros VG, Karagiannis A. The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. Hormones (Athens) 2018;17:83-95. [PMID: 29858866 DOI: 10.1007/s42000-018-0017-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
90 Mashitisho M, Mashitisho B. Early insulin therapy in patients with type 2 diabetes mellitus. Journal of Endocrinology, Metabolism and Diabetes of South Africa 2015;21:13-5. [DOI: 10.1080/16089677.2016.1160539] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
91 Gebrie D, Manyazewal T, A Ejigu D, Makonnen E. Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia. Diabetes Metab Syndr Obes 2021;14:3345-59. [PMID: 34335036 DOI: 10.2147/DMSO.S312997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ 2018;362:k2693. [PMID: 30021781 DOI: 10.1136/bmj.k2693] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 9.5] [Reference Citation Analysis]
93 Floyd JS, Wiggins KL, Sitlani CM, Flory JH, Dublin S, Smith NL, Heckbert SR, Psaty BM. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. Diabetes Obes Metab 2015;17:1194-7. [PMID: 26179389 DOI: 10.1111/dom.12537] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
94 Yen FS, Hsu CC, Su YC, Wei JC, Hwu CM. Impacts of early insulin treatment vs glimepiride in diabetic patients with background metformin therapy: A nationwide retrospective cohort study. Medicine (Baltimore) 2021;100:e25085. [PMID: 33655987 DOI: 10.1097/MD.0000000000025085] [Reference Citation Analysis]
95 Zhu J, Yu X, Zheng Y, Li J, Wang Y, Lin Y, He Z, Zhao W, Chen C, Qiu K, Wu J. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. The Lancet Diabetes & Endocrinology 2020;8:192-205. [DOI: 10.1016/s2213-8587(19)30422-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 26.0] [Reference Citation Analysis]
96 Ouyang J, Isnard S, Lin J, Fombuena B, Marette A, Routy B, Chen Y, Routy JP. Metformin effect on gut microbiota: insights for HIV-related inflammation. AIDS Res Ther 2020;17:10. [PMID: 32156291 DOI: 10.1186/s12981-020-00267-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
97 Bittencourt MS, Hajjar LA. Insulin therapy in insulin resistance: Could it be part of a lethal pathway? Atherosclerosis 2015;240:400-1. [DOI: 10.1016/j.atherosclerosis.2015.04.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
98 Li TC, Li CI, Liu CS, Lin WY, Lin CH, Yang SY, Lin CC. Derivation and validation of 10-year all-cause and cardiovascular disease mortality prediction model for middle-aged and elderly community-dwelling adults in Taiwan. PLoS One 2020;15:e0239063. [PMID: 32925948 DOI: 10.1371/journal.pone.0239063] [Reference Citation Analysis]
99 Weinrauch LA, D’elia JA, Finn P, Lewis EF, Desai AS, Claggett BL, Cooper ME, Mcgill JB. Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study). Diabetes Research and Clinical Practice 2016;113:143-51. [DOI: 10.1016/j.diabres.2015.12.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
100 Anyanwagu U, Mamza J, Donnelly R, Idris I. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study. Am Heart J 2018;196:18-27. [PMID: 29421011 DOI: 10.1016/j.ahj.2017.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
101 Wang YC, Tang A, Chang D, Lu CQ, Zhang SJ, Ju S. Long-Term Adverse Effects of Low-Osmolar Compared With Iso-Osmolar Contrast Media After Coronary Angiography. Am J Cardiol 2016;118:985-90. [PMID: 27521223 DOI: 10.1016/j.amjcard.2016.07.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
102 Xu S, Wang B, Liu W, Wu C, Huang J. The effects of insulin therapy on mortality in diabetic patients undergoing percutaneous coronary intervention. Ann Transl Med 2021;9:1294. [PMID: 34532431 DOI: 10.21037/atm-21-1911] [Reference Citation Analysis]
103 Kolb H, Kempf K, Röhling M, Martin S. Insulin: too much of a good thing is bad. BMC Med 2020;18:224. [PMID: 32819363 DOI: 10.1186/s12916-020-01688-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
104 Lee KT, Yeh YH, Chang SH, See LC, Lee CH, Wu LS, Liu JR, Kuo CT, Wen MS. Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study. Medicine (Baltimore) 2017;96:e7507. [PMID: 28700501 DOI: 10.1097/MD.0000000000007507] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
105 Thomsen RW, Baggesen LM, Søgaard M, Pedersen L, Nørrelund H, Buhl ES, Haase CL, Johnsen SP. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes. Diabetologia 2015;58:2247-53. [PMID: 26277380 DOI: 10.1007/s00125-015-3698-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
106 Ali SM, Chen P, Sheikh S, Ahmad A, Ahmad M, Paithankar M, Desai B, Patel P, Khan M, Chaturvedi A, Patel R, Panchal DT, Shah K, Chavda V, Saboo BD, Patel A, Ahmad I. Thymoquinone with Metformin Decreases Fasting, Post Prandial Glucose, and HbA1c in Type 2 Diabetic Patients. Drug Res (Stuttg) 2021;71:302-6. [PMID: 33684953 DOI: 10.1055/a-1388-5415] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Ioacara S, Guja C, Reghina A, Martin S, Sirbu A, Fica S. Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine. J Diabetes Res 2015;2015:962346. [PMID: 26176017 DOI: 10.1155/2015/962346] [Reference Citation Analysis]